Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
Journal
Journal for immunotherapy of cancer
Journal Volume
11
Journal Issue
11
Date Issued
2023-11-29
Author(s)
Bauer, Todd M
Santoro, Armando
Garrido-Laguna, Ignacio
Joerger, Markus
Greil, Richard
Spreafico, Anna
Yau, Thomas
Goebeler, Maria-Elisabeth
Hütter-Krönke, Marie Luise
Perotti, Antonella
Juif, Pierre-Eric
Lu, Darlene
Barys, Louise
Cremasco, Viviana
Pelletier, Marc
Evans, Helen
Fabre, Claire
Doi, Toshikiko
Abstract
NIS793 is a human IgG2 monoclonal antibody that binds to transforming growth factor beta (TGF-β). This first-in-human study investigated NIS793 plus spartalizumab treatment in patients with advanced solid tumors.
Subjects
Drug Therapy, Combination; Immunotherapy; Non-Small Cell Lung Cancer; Programmed Cell Death 1 Receptor; Therapies, Investigational
SDGs
Type
journal article